MAPT and frontotemporal dementia: Importantly, clearance of tau was observed in a disease context, in FTD patient-derived neurons, where the ALP is already affected, revealing that this pathway can be pharmacologically enhanced to rescue tau pathogenicity and possibly neurodegeneration.